Research programme: Zika virus vaccine - Immunovaccine

Drug Profile

Research programme: Zika virus vaccine - Immunovaccine

Latest Information Update: 15 Sep 2016

Price : $50

At a glance

  • Originator Immunovaccine
  • Class Synthetic vaccines; Zika virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Zika virus infection

Most Recent Events

  • 15 Sep 2016 Preclinical trials in Zika virus infection (Prevention) in Canada (Parenteral)
  • 07 Apr 2016 Immunovaccine and Leidos collaborate to develop Zika virus vaccine
  • 03 Mar 2016 Early research in Zika virus infection in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top